Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Blood and Transplant

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

- PMLiVE

NHS expands diagnostic capabilities to reform cancer standards for patients

Thousands of patients are set to receive faster diagnosis and treatment

- PMLiVE

NHS achieves new record for cancer checks for patients

Nearly three million patients have had cancer checks by the NHS in the last year

- PMLiVE

UK government allocates £250m for more NHS hospital beds in England

The funds will provide another 5,000 beds this winter to relieve pressure on hospitals and cut waiting times

- PMLiVE

NHS to initiate flu vaccine roll-outs for children from September

The roll-outs are part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

NHS England to offer millions of children flu vaccines from September

The rollout is part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

New NHS treatments increase survival rates for babies with spinal muscular atrophy

Around 70 babies are born with the rare muscle-wasting disease each year in the UK

- PMLiVE

Sanofi and Scribe announce in vivo genetic therapy partnership worth over $1.2bn

The agreement expands the companies’ existing collaboration focused on ex vivo editing

- PMLiVE

NHS extends eligibility for shingles vaccine to almost one million people

Approximately one in four people will develop shingles and the risk increases with age

- PMLiVE

NHS launches plans to expand drug contracts to develop new life-saving antibiotics

New antibiotics could reduce death rates and ensure future pandemic preparedness

- PMLiVE

bluebird bio’s sickle cell gene therapy accepted for FDA priority review

The genetic disease affects approximately 100,000 people in the US

EU flag

EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug

The EU regulator concluded that the benefits of Adakveo did not outweigh its risks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links